Addressing Shortages and High Prices of Life-Saving Medications

To address the critical risks posed to patients from chronic shortages and rising prices of life-saving generic medications, the Peterson Center on Healthcare has committed $15 million to help support Civica Rx, a not-for-profit generic drug company.

The Center has joined with Arnold Ventures, the Gary and Mary West Foundation, and over 55 U.S. health systems—representing more than 1,500 U.S. hospitals—to stabilize the supply of essential medications by ensuring affordability and availability.

As members of the Civica Board of Directors, the three foundations will work to further support and safeguard the company’s non-profit, social welfare mission to provide affordable, essential generic drugs to ensure a predictable supply and competitive marketplace.

To date, Civica has provided over 70 million vials or syringes of 60 essential generic medications to hospitals, which have been used to treat more than 28 million patients.

Civica has expanded its mission to reach individuals and families buying generic prescriptions in pharmacies. Through a partnership with the Blue Cross Blue Shield Association and 18 independent and locally-operated Blue Cross and Blue Shield companies, Civica launched a subsidiary dedicated to lowering the cost of select generic drugs. The subsidiary is being formed in response to the impact of high drug costs on the health of Americans and the overall affordability of healthcare. Other health plans, employers, retail partners and healthcare innovators who share the belief that patients and their needs come first are invited to join the initiative.

EmsanaRx Joins CivicaScript to Make Lower-Cost Generic Medicines Available to its Pharmacy Benefit Members

Read the Press Release

Civica Selects Profil as Clinical Trial Partner for Affordable Insulin Initiative

Read the Press Release

CivicaScript, the Newly Named Civica Initiative to Serve Patients in Retail Markets, Announces a New Health Plan Partner, a New President, and a New Drug Manufacturing Partner

Read the Press Release